Omega Therapeutics, Inc. (OMGA): Price and Financial Metrics
OMGA Price/Volume Stats
| Current price | $8.06 | 52-week high | $11.98 |
| Prev. close | $7.20 | 52-week low | $2.05 |
| Day low | $7.23 | Volume | 98,200 |
| Day high | $8.20 | Avg. volume | 88,810 |
| 50-day MA | $7.85 | Dividend yield | N/A |
| 200-day MA | $6.53 | Market Cap | 443.49M |
OMGA Stock Price Chart Interactive Chart >
OMGA POWR Grades
- Sentiment is the dimension where OMGA ranks best; there it ranks ahead of 88.98% of US stocks.
- OMGA's strongest trending metric is Growth; it's been moving down over the last 179 days.
- OMGA's current lowest rank is in the Quality metric (where it is better than 5.41% of US stocks).
OMGA Stock Summary
- OMGA's went public 1.82 years ago, making it older than merely 4.05% of listed US stocks we're tracking.
- OMGA's price/sales ratio is 207.82; that's higher than the P/S ratio of 98.28% of US stocks.
- Revenue growth over the past 12 months for OMEGA THERAPEUTICS INC comes in at 463.59%, a number that bests 98.27% of the US stocks we're tracking.
- Stocks that are quantitatively similar to OMGA, based on their financial statements, market capitalization, and price volatility, are MGNX, STTK, PIRS, BOLT, and IPSC.
- To dig deeper into the stock's financial statements, go to OMGA's page on browse-edgar?action=getcompany&CIK=0001850838.
OMGA Valuation Summary
- OMGA's price/sales ratio is 228.9; this is 4388.24% higher than that of the median Healthcare stock.
- Over the past 22 months, OMGA's price/earnings ratio has gone up 20.5.
Below are key valuation metrics over time for OMGA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OMGA | 2023-05-23 | 228.9 | 4.3 | -4.9 | -4.1 |
| OMGA | 2023-05-22 | 228.0 | 4.3 | -4.9 | -4.1 |
| OMGA | 2023-05-19 | 209.7 | 4.0 | -4.5 | -3.7 |
| OMGA | 2023-05-18 | 208.5 | 3.9 | -4.5 | -3.7 |
| OMGA | 2023-05-17 | 218.0 | 4.1 | -4.7 | -3.9 |
| OMGA | 2023-05-16 | 197.6 | 3.7 | -4.3 | -3.5 |
Omega Therapeutics, Inc. (OMGA) Company Bio
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest OMGA News From Around the Web
Below are the latest news stories about OMEGA THERAPEUTICS INC that investors may wish to consider to help them evaluate OMGA as an investment opportunity.
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryFlagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications. |
Investors in Omega Therapeutics (NASDAQ:OMGA) have seen impressive returns of 177% over the past yearThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you... |
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 48.23%: Read This Before Placing a BetThe mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 48.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Misses Revenue EstimatesOmega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressContinued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate OTX-2002 in Combination with Atezolizumab in MYCHELANGELO I StudyAdvanced Other Pipeline Programs and OMEGA Platform DevelopmentCash, Cash Equivalents and Marketable Securities of $136.8 Million as of March 31, 2023 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) |
OMGA Price Returns
| 1-mo | 0.00% |
| 3-mo | 19.76% |
| 6-mo | 19.05% |
| 1-year | 256.64% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 41.16% |
| 2022 | -49.60% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...